Lactoferrin-modified niclosamide lipid nanocarriers reprogram ferroptosis and antioxidant networks for breast cancer suppression.

Repurposing niclosamide (Nic), an FDA-approved anthelmintic with emerging anticancer potential, offers a promising strategy for breast cancer therapy. However, its clinical translation is limited by poor solubility and bioavailability. In this study,…

Preview only. Read the full abstract at the source